Replies to post #201698 on Biotech Values

[DewDiligence]

It's possible (probable?) that ENTA's cyclophilin inhibitor also has activity against hep B.

Not especially likely, IMO; if EDP-494 had activity against HBV, ENTA probably would have said so by now and they might have included an HBV cohort in the phase-1 trial (https://clinicaltrials.gov/ct2/show/NCT02652377 ).